NovaBay Pharmaceuticals (NBY)
Market Price (3/31/2026): $1.36 | Market Cap: $1.7 MilSector: Health Care | Industry: Biotechnology
NovaBay Pharmaceuticals (NBY)
Market Price (3/31/2026): $1.36Market Cap: $1.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -424% | Weak multi-year price returns2Y Excs Rtn is -113%, 3Y Excs Rtn is -160% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.6 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1311% | ||
| High stock price volatilityVol 12M is 354% | ||
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 27% | ||
| Key risksNBY key risks include [1] its precarious financial health and substantial going concern doubts, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -424% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease. Themes include Geriatric Care, and Diabetes Management. |
| Weak multi-year price returns2Y Excs Rtn is -113%, 3Y Excs Rtn is -160% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.6 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1311% |
| High stock price volatilityVol 12M is 354% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 27% |
| Key risksNBY key risks include [1] its precarious financial health and substantial going concern doubts, Show more. |
Qualitative Assessment
AI Analysis | Feedback
NovaBay Pharmaceuticals (NBY) stock has lost about 75% since 11/30/2025 because of the following key factors:
1. Continued Weak Financial Performance: NovaBay Pharmaceuticals reported significant operating losses within the period, with Q4 2025 earnings announcing a net loss of -$26.6 million. The company's overall fiscal year 2025 also concluded with a net loss of -$22.1 million, reflecting ongoing financial struggles and lower returns on assets and capital employed compared to industry averages.
2. Significant Share Dilution: The company experienced substantial shareholder dilution, with total shares outstanding growing by 2145.9% in the past year. This was exacerbated by shareholder approval on March 12, 2026, to increase authorized common stock to 5 billion shares and to issue shares underlying pre-funded warrants from private placements, including a $134 million private placement in January 2026 that involved issuing 167,539,226 common shares (post-split).
Show more
1. Continued Weak Financial Performance: NovaBay Pharmaceuticals reported significant operating losses within the period, with Q4 2025 earnings announcing a net loss of -$26.6 million. The company's overall fiscal year 2025 also concluded with a net loss of -$22.1 million, reflecting ongoing financial struggles and lower returns on assets and capital employed compared to industry averages.
2. Significant Share Dilution: The company experienced substantial shareholder dilution, with total shares outstanding growing by 2145.9% in the past year. This was exacerbated by shareholder approval on March 12, 2026, to increase authorized common stock to 5 billion shares and to issue shares underlying pre-funded warrants from private placements, including a $134 million private placement in January 2026 that involved issuing 167,539,226 common shares (post-split).
Show more
Stock Movement Drivers
Fundamental Drivers
The -75.2% change in NBY stock from 11/30/2025 to 3/30/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 3302026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.45 | 1.35 | -75.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | |
| P/S Multiple | 12.3 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 1 | 1 | -6.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/30/2026| Return | Correlation | |
|---|---|---|
| NBY | -75.2% | |
| Market (SPY) | -5.3% | 1.9% |
| Sector (XLV) | -8.4% | 15.7% |
Fundamental Drivers
The -77.1% change in NBY stock from 8/31/2025 to 3/30/2026 was primarily driven by a -7.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3302026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.88 | 1.35 | -77.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 1 | -7.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/30/2026| Return | Correlation | |
|---|---|---|
| NBY | -77.1% | |
| Market (SPY) | 0.6% | 4.5% |
| Sector (XLV) | 5.6% | 10.7% |
Fundamental Drivers
The -32.5% change in NBY stock from 2/28/2025 to 3/30/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3302026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.00 | 1.35 | -32.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 0 | |
| P/S Multiple | 0.2 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 0 | 1 | -81.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/30/2026| Return | Correlation | |
|---|---|---|
| NBY | -32.5% | |
| Market (SPY) | 9.8% | 3.0% |
| Sector (XLV) | -1.7% | 8.0% |
Fundamental Drivers
The -99.5% change in NBY stock from 2/28/2023 to 3/30/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3302026 | Change |
|---|---|---|---|
| Stock Price ($) | 266.06 | 1.35 | -99.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 14 | 0 | |
| P/S Multiple | 0.2 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 0 | 1 | -99.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/30/2026| Return | Correlation | |
|---|---|---|
| NBY | -99.5% | |
| Market (SPY) | 69.4% | 3.1% |
| Sector (XLV) | 18.9% | 4.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NBY Return | -46% | -85% | -90% | -92% | 1320% | -95% | -100% |
| Peers Return | -21% | -33% | 105% | 43% | 55% | -39% | 45% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -7% | 70% |
Monthly Win Rates [3] | |||||||
| NBY Win Rate | 25% | 17% | 17% | 25% | 50% | 33% | |
| Peers Win Rate | 33% | 43% | 48% | 50% | 55% | 27% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| NBY Max Drawdown | -46% | -90% | -90% | -95% | -21% | -98% | |
| Peers Max Drawdown | -42% | -62% | -50% | -27% | -41% | -44% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TARS, SNOA, OCUL, EYPT, ALDX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/30/2026 (YTD)
How Low Can It Go
| Event | NBY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.6% | -25.4% |
| % Gain to Breakeven | 24434.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -67.7% | -33.9% |
| % Gain to Breakeven | 209.6% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -94.1% | -19.8% |
| % Gain to Breakeven | 1596.4% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -74.8% | -56.8% |
| % Gain to Breakeven | 297.0% | 131.3% |
| Time to Breakeven | Not Fully Recovered days | 1,480 days |
Compare to TARS, SNOA, OCUL, EYPT, ALDX
In The Past
NovaBay Pharmaceuticals's stock fell -99.6% during the 2022 Inflation Shock from a high on 2/18/2021. A -99.6% loss requires a 24434.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About NovaBay Pharmaceuticals (NBY)
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
AI Analysis | Feedback
Here are 1-3 brief analogies for NovaBay Pharmaceuticals (NBY):
CeraVe for specific skin conditions, plus niche eye care.
A small Bausch Health focused on consumer eye and skin products.
A niche Perrigo for eye and skin health.
AI Analysis | Feedback
```html- Avenova: A solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid.
- NeutroPhase: A brand of wound care products.
- PhaseOne: A brand of wound care products.
- DERMAdoctor brand products: Dermatological solutions addressing skincare concerns such as keratosis pilaris, rosacea, eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne.
AI Analysis | Feedback
NovaBay Pharmaceuticals (NBY) primarily sells its products to other companies. Based on the provided background, its major customers fall into the following categories:
- Retailers
- Digital beauty channels
- Distributors
The provided background does not list specific names of these customer companies or their public symbols.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here is the management team for NovaBay Pharmaceuticals, Inc.:Michael Kazley, Chief Executive Officer
Michael Kazley was appointed Chief Executive Officer and Chairman of the Board of NovaBay Pharmaceuticals, Inc. effective October 16, 2025. Prior to joining NovaBay, Mr. Kazley served as the Managing Member and General Partner of R01 Fund LP since 2023. He has extensive experience in investment management and digital asset markets.
Tommy Law, Chief Financial Officer
Tommy Law was appointed Chief Financial Officer of NovaBay Pharmaceuticals, Inc. effective August 19, 2025. He previously served as the company’s Interim Chief Financial Officer and Treasurer starting in February 2023. Mr. Law joined NovaBay in December 2019 and has held various positions, including Corporate Controller since September 2022, Assistant Controller, Accounting Manager, and Senior Accountant. Before NovaBay, he was a Senior Accountant at KP LLC from January 2017 to December 2019, and an Accounting Manager at Hitachi Solutions America Ltd. from 2012 to 2015. Mr. Law holds a B.S. in Business Administration, Accounting, from San Jose State University.
AI Analysis | Feedback
The key risks to NovaBay Pharmaceuticals (NBY) are primarily related to its recent corporate restructuring and uncertain future direction:
- Uncertainty of Strategic Alternatives and Potential for Dissolution: NovaBay Pharmaceuticals divested its primary assets, including DERMAdoctor, Avenova, and PhaseOne, in 2025. The company is now focused on pursuing strategic alternatives such as mergers, acquisitions, or developing a new product pipeline. A significant risk to the business is the possibility that these strategic alternatives may not materialize, which could lead to the company's dissolution and substantial losses for shareholders.
- Share Dilution and Stock Price Volatility: To meet NYSE American equity requirements and secure capital, NovaBay has engaged in financial maneuvers like private placements of pre-funded warrants and at-the-market sales agreements. While these actions aim to bolster the company's financial position, they introduce a considerable risk of dilution for existing shareholders. Furthermore, the stock has shown extreme volatility, with significant price fluctuations often driven by speculation rather than underlying business fundamentals.
- Lack of a Viable Ongoing Business and Persistent Operating Losses: Following the sale of its core products, NovaBay Pharmaceuticals currently lacks an active product pipeline. The company has reported significant net losses and a decline in revenue over the past three and five years. Its financial health metrics, including a Z-Score in the distress zone and deeply negative operating margins, highlight ongoing sustainability issues, making its future dependent on the successful execution of its new strategic direction.
AI Analysis | Feedback
nullAI Analysis | Feedback
NovaBay Pharmaceuticals, Inc. operates in several addressable markets with its eyecare, wound care, and dermatological product lines.
Eyecare (Avenova)
- The global eyelid scrub market was valued at approximately USD 3.56 billion in 2024 and is projected to reach around USD 7.00 billion by 2034, growing at a CAGR of 7.0% from 2025 to 2034.
- In 2024, North America held the largest share of the global eyelid scrub market, with a revenue of USD 1.31 billion. The North American eyelid scrub market is projected to grow due to an advanced ophthalmic care sector, rising incidence of dry eye syndrome, and high consumer awareness regarding eye hygiene.
Wound Care (NeutroPhase, PhaseOne)
- The U.S. wound care market was valued at USD 8.63 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 4.11% from 2024 to 2030. Another estimate indicates the U.S. wound care market was valued at USD 7.5 billion in 2025 and is projected to reach USD 12.5 billion by 2035, expanding at a CAGR of 5.4% from 2026.
- The global wound care centers market was valued at USD 45.17 billion in 2024 and is expected to reach approximately USD 64.49 billion by 2034, growing at an annual rate of 3.64% from 2025 to 2034.
Dermatological Solutions (DERMAdoctor brand for keratosis pilaris, rosacea, eczema, anti-aging, SPF, hyperhidrosis, acne)
- Keratosis Pilaris: The global keratosis pilaris treatment market was estimated at US$ 7.3 billion in 2024 and is expected to reach US$ 13.34 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2025-2033. North America is expected to dominate this market.
- Rosacea: The global rosacea treatment market was valued at USD 2.07 billion in 2023 and is expected to reach USD 3.70 billion by 2032, growing at a CAGR of 6.64% from 2024 to 2032. North America dominated the global market with the largest market share of 39% in 2024.
- Eczema: The global eczema market size was valued at USD 16.41 billion in 2024 and is projected to grow to USD 24.35 billion in 2029 at a CAGR of 8.1%. Another source indicates the global atopic eczema treatment market was worth around USD 19.73 billion in 2024 and is predicted to grow to around USD 51.26 billion by 2034 with a CAGR of roughly 9.2% between 2025 and 2034. North America contributed about half of the global atopic eczema treatment market revenue in 2022.
- Anti-aging: The global anti-aging market size was calculated at USD 77.96 billion in 2025 and is predicted to increase to approximately USD 149.54 billion by 2035, expanding at a CAGR of 6.73% from 2026 to 2035. The U.S. anti-aging market size was calculated at US$ 20.21 billion in 2024 and is projected to reach around US$ 39.6 billion by 2034.
- Hyperhidrosis: The global hyperhidrosis treatment market size was valued at USD 1.74 billion in 2024 and is anticipated to grow from USD 1.81 billion in 2025 to reach USD 2.5 billion by 2033, exhibiting a CAGR of 4.07% during the forecast period (2025–2033). North America's hyperhidrosis treatment market was valued at USD 280.7 million in 2023 and is anticipated to grow with a CAGR of 5% to reach USD 437.2 million by 2032.
- Acne: The global acne treatment market size was valued at USD 12.19 billion in 2025 and is projected to grow from USD 12.80 billion in 2026 to USD 19.55 billion by 2034, exhibiting a CAGR of 5.40% during the forecast period. North America dominated the acne treatment market with a market share of 48.71% in 2025.
- SPF (Sunscreen): The global sunscreen cream market size was valued at USD 7857.17 million in 2025 and is poised to grow to USD 13066.49 million by 2035, growing at a CAGR of 5.2% during the forecast period (2026 - 2035). North America consumed 1.14 billion units of sunscreen cream in 2023, representing 27% of global volume. The U.S. sun care cosmetics market size was estimated at USD 1,977.7 million in 2024.
AI Analysis | Feedback
NovaBay Pharmaceuticals (NBY) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Increased Sales of Avenova through Online and Subscription Channels: The company has demonstrated robust growth in its flagship Avenova product line, particularly through direct-to-consumer (DTC) online channels, including Amazon.com. The "Subscribe & Save" program has been identified as a significant driver of recurring revenue, with a substantial increase in customers.
- Strategic Focus on the Growing Dry Eye Market: NovaBay has strategically pivoted to concentrate on the eyecare market, specifically targeting dry eye conditions. This market is projected to expand significantly, reaching nearly $5 billion in the US by 2030, providing a substantial opportunity for Avenova's continued growth.
- Expansion and Efficiency in Digital Marketing: The company's expertise in digital marketing has led to more efficient customer engagement and a loyal customer base, contributing to revenue growth while simultaneously reducing sales and marketing expenses. This optimized approach supports sustained growth in its eyecare segment.
- Introduction of New Prescription Eyecare Products: The launch of Avenova Allograft, a prescription-only amniotic membrane product, in Q3 2023, targets a large and growing market. This new product, with its potential for Medicare coverage, is anticipated to be a significant contributor to future revenue.
- Pursuit of Strategic Partnerships and Fundamental Transactions: NovaBay's management has indicated a focus on exploring strategic partnerships and fundamental transactions in the near future, which could unlock new avenues for market expansion and revenue generation.
AI Analysis | Feedback
NovaBay Pharmaceuticals (NBY) has undertaken several capital allocation decisions over the last 3-5 years.Share Issuance
- On October 21, 2025, NovaBay Pharmaceuticals insider David E. Lazar reported the automatic conversion of 39,925 shares of Series D Convertible Preferred Stock into 6,388,000 shares of common stock at no additional cost.
- Stockholders were asked to vote on proposals to approve the issuance of NovaBay common stock upon exercise of pre-funded warrants issued in private placements on January 16, 2026, and October 16, 2025.
- The company implemented a 1-for-5 reverse stock split on February 20, 2026, reducing issued and outstanding shares from approximately 130,623,400 to approximately 26,124,680. This followed earlier reverse splits of 1:35 on May 31, 2024, and November 16, 2022.
Inbound Investments
- NovaBay Pharmaceuticals entered into a $6 million Securities Purchase Agreement with investor David E. Lazar on August 19, 2025.
- SEC filings outlined a Securities Purchase Agreement for Series D and Series E non-voting convertible preferred stock, which upon conversion and subject to stockholder approval, would represent in excess of 90% of NovaBay's fully diluted common stock as of the final closing.
Capital Expenditures
- In the last 12 months, NovaBay Pharmaceuticals reported capital expenditures of -$4,000, contributing to a free cash flow of $2.95 million.
- Another report for the last 12 months indicated capital expenditures of $0, with an operating cash flow of -$6.97 million.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to NBY.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.74 |
| Mkt Cap | 0.5 |
| Rev LTM | 25 |
| Op Inc LTM | -53 |
| FCF LTM | -28 |
| FCF 3Y Avg | -57 |
| CFO LTM | -23 |
| CFO 3Y Avg | -53 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.2% |
| Rev Chg 3Y Avg | 7.1% |
| Rev Chg Q | -0.2% |
| QoQ Delta Rev Chg LTM | -6.9% |
| Op Mgn LTM | -267.7% |
| Op Mgn 3Y Avg | -305.4% |
| QoQ Delta Op Mgn LTM | -33.6% |
| CFO/Rev LTM | -207.1% |
| CFO/Rev 3Y Avg | -241.2% |
| FCF/Rev LTM | -219.2% |
| FCF/Rev 3Y Avg | -253.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.5 |
| P/S | 18.9 |
| P/EBIT | -3.7 |
| P/E | -3.6 |
| P/CFO | -3.6 |
| Total Yield | -28.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -13.8% |
| D/E | 0.1 |
| Net D/E | -0.5 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -22.9% |
| 3M Rtn | -40.8% |
| 6M Rtn | -44.2% |
| 12M Rtn | -8.2% |
| 3Y Rtn | -21.3% |
| 1M Excs Rtn | -15.1% |
| 3M Excs Rtn | -33.4% |
| 6M Excs Rtn | -40.3% |
| 12M Excs Rtn | -27.7% |
| 3Y Excs Rtn | -76.2% |
Price Behavior
Price Behavior
| Market Price | $1.35 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 10/26/2007 | |
| Distance from 52W High | -98.6% | |
| 50 Days | 200 Days | |
| DMA Price | $6.49 | $8.86 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -79.2% | -84.8% |
| 3M | 1YR | |
| Volatility | 622.8% | 355.6% |
| Downside Capture | 1.30 | 0.13 |
| Upside Capture | -1492.40 | -26.41 |
| Correlation (SPY) | -1.5% | 3.3% |
NBY Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -15.89 | -3.03 | -1.18 | 0.74 | 0.37 | 0.39 |
| Up Beta | 21.72 | 19.42 | 15.49 | 11.38 | 0.58 | 0.40 |
| Down Beta | -31.89 | 2.05 | 2.37 | -0.65 | 1.27 | 1.36 |
| Up Capture | -1453% | -789% | -485% | -144% | -19% | -7% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 5 | 12 | 26 | 57 | 117 | 327 |
| Down Capture | -326% | 237% | -301% | 112% | -11% | 99% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 16 | 29 | 34 | 65 | 127 | 408 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NBY | |
|---|---|---|---|---|
| NBY | -33.0% | 354.2% | 1.14 | - |
| Sector ETF (XLV) | 0.6% | 17.6% | -0.12 | 8.5% |
| Equity (SPY) | 14.8% | 19.0% | 0.60 | 3.2% |
| Gold (GLD) | 48.2% | 27.7% | 1.42 | 7.0% |
| Commodities (DBC) | 17.5% | 17.6% | 0.83 | 3.1% |
| Real Estate (VNQ) | 1.1% | 16.4% | -0.11 | 4.6% |
| Bitcoin (BTCUSD) | -24.0% | 44.3% | -0.49 | 5.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NBY | |
|---|---|---|---|---|
| NBY | -80.0% | 181.4% | -0.18 | - |
| Sector ETF (XLV) | 6.3% | 14.5% | 0.25 | 4.0% |
| Equity (SPY) | 12.0% | 17.0% | 0.55 | 4.5% |
| Gold (GLD) | 20.9% | 17.7% | 0.97 | 6.2% |
| Commodities (DBC) | 12.2% | 18.8% | 0.53 | 2.5% |
| Real Estate (VNQ) | 3.2% | 18.8% | 0.07 | 1.6% |
| Bitcoin (BTCUSD) | 3.9% | 56.6% | 0.29 | 4.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NBY | |
|---|---|---|---|---|
| NBY | -58.7% | 342.6% | 0.29 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 1.1% |
| Equity (SPY) | 13.9% | 17.9% | 0.67 | 3.4% |
| Gold (GLD) | 13.4% | 15.8% | 0.70 | -0.8% |
| Commodities (DBC) | 8.2% | 17.6% | 0.38 | 2.8% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | 0.3% |
| Bitcoin (BTCUSD) | 66.2% | 66.9% | 1.06 | 4.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/23/2026 | 19.0% | 29.3% | |
| 7/11/2024 | 5.2% | -2.8% | -82.1% |
| 3/14/2024 | -4.9% | -1.1% | -36.2% |
| 7/21/2020 | -23.0% | -28.6% | -34.2% |
| SUMMARY STATS | |||
| # Positive | 2 | 1 | 0 |
| # Negative | 2 | 3 | 3 |
| Median Positive | 12.1% | 29.3% | |
| Median Negative | -13.9% | -2.8% | -36.2% |
| Max Positive | 19.0% | 29.3% | |
| Max Negative | -23.0% | -28.6% | -82.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/19/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/02/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/26/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.58 | 917 | 532 | 575,642 | Form | |
| 2 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.56 | 22,976 | 12,929 | 571,400 | Form | |
| 3 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.52 | 4,538 | 2,367 | 532,032 | Form | |
| 4 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.47 | 300 | 140 | 474,440 | Form | |
| 5 | Poplar, Point Capital Partners Lp | Direct | Buy | 4142025 | 0.61 | 13,292 | 8,095 | 536,831 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.